GSK expedites Blenrep timelines as it eyes second chance in multiple myeloma
GSK wants to present Blenrep to regulatory bodies sooner.
The UK pharma will submit Blenrep in second-line multiple myeloma to US, European and Japanese authorities in the second half of 2024, which is earlier than the original 2025 guidance, according to its first-quarter earnings report. The filings will be based on positive outcomes from the Phase 3 DREAMM-7 and DREAMM-8 studies reported earlier this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
